Work

HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps629

Authors: Joyce O'Shaughnessy, Julie Marie Collins, Lili Yao, Karen L. Smith, Jaime A. Mejia, Michael A. Danso

Institutions: Baylor University Medical Center, Daiichi Sankyo (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Virginia Oncology Associates

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410820287

FWCI:

Cites:

Cited by:

Related to: 10